BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PF-08642534 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PF-08642534\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07731139-11277@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20270421
DTEND;VALUE=DATE:20270422
SUMMARY:PF-08642534: Phase 1 readout est. (NCT07731139)
DESCRIPTION:PF-08642534\, phase 1\, Obesity.\nStudy: A Study to Learn How D
 ifferent Amounts of the Study Medicine Called PF-08642534 Are Tolerated an
 d Act in the Body of People Who Have Obesity\nEstimated primary completion
 : 21 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-0
 8642534#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07731139
URL:https://assetmemo.bio/drug/pf-08642534#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
